PPIB and congestive heart failure: Silencing salusin-β contributes to the improvement of endothelial function, cardiac function, and cardiovascular remodeling in CHF by inhibiting NAD(P)H oxidase-derived ROS generation and activating eNOS and NO production, which provides a new strategy and target for the treatment of chronic heart failure in the future.